Back to Barclays plc Barclays plc

AXSMAXSM

Showing 8 of 28 quarters

Position history for Barclays plcBarclays plc's holdings in Axsome Therapeutics, Inc.

Yes. Barclays holds 51,203 shares of AXSM (Axsome Therapeutics), worth $12.5M, as of its Q2 2026 13F filing. It increased the position by 16,942 shares (+49.5%) from Q1 2026. Barclays has held AXSM since Q2 2023, across 13 quarterly 13F filings.

Current Value

$12.5M

Current Shares

51,203

Total Value Change

+$7M

Total Shares Change

-10,582

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
51,203
+49.5%
$12.5M0.0%$244.77
39
2026-Q1
Decreased
34,261
-55.4%
$5.8M0.0%$169.02
0
2025-Q4
Increased
76,853
+6.6%
$14M0.0%$182.64
30
2025-Q3
Decreased
72,067
-26.1%
$8.8M0.0%$121.45
0
2025-Q2
Increased
97,490
+88.0%
$10.2M0.0%$104.39
43
2025-Q1
Decreased
51,870
-47.1%
$6M0.0%$116.63
0
2024-Q4
Increased
97,988
+58.6%
$8.3M0.0%$84.61
39
2024-Q3
Increased
61,785
+279.6%
$5.6M0.0%$89.87
44

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used